At present, artificial intelligence technology has gradually matured and made a breakthrough in the field of medical health. Application scenarios such as artificial intelligence combined with medical imaging, auxiliary diagnosis, and empowering new drug research and development continue to land. The popularity of the artificial intelligence medical industry has increased. In 2020, China's investment in AI medical field reached 6.409 billion yuan, up by 1.4 1.9% year-on-year. Even Tencent, Ali, Huawei and other technology giants have also entered the game.
What is more gratifying is that AI medical imaging has been commercialized successfully in the medical and health field. Ma Chunxi, co-founder and CEO of Jikun Technology, revealed at the summit that the AI products of Jikun Technology have been frequently used by clinicians in the top three and primary hospitals. Ji Kun is working hard to expand the use of AI products in primary hospitals and help more primary patients enjoy better medical service resources as soon as possible.
In the future, AI+ medical care will lead the new trend of digital medical care.
Emerging technologies and medical and health industries are accelerating their integration, and the capital market is also opening its doors to innovative medical technology companies. Therefore, AI medical care has also become the highlight of this summit.
"In the hospital space, early application of ambient intelligence can make the clinical workflow more effective and improve the safety of patients in the intensive care unit and operating room." Li Feifei, a professor at Stanford University, believes that for future family scenes, most elderly people will spend most of their time at home. AI sensors will help the elderly to be more independent in their daily lives, and carry out chronic disease management and physical rehabilitation treatment through daily data collection.
Under the perfect opening of Professor Li Feifei on the topic of AI medical treatment, leading domestic artificial intelligence enterprises such as Huawei, Tencent, Baidu, Jikun Technology and Iflytek pushed the discussion on the future trend of "AI+ medical treatment" to a climax.
Wu Wenda, an expert of the Digital Medical Technology Advisory Committee of the World Health Organization and vice president of Tencent Medical, believes that the demand for AI images is now in short supply, which has improved the work efficiency of many doctors.
Tao Xiaodong, president of Iflytek Medical, also believes that medical AI is still essentially for doctors and patients. "Artificial intelligence has shown its value in many fields, including auxiliary diagnosis, imaging and precise matching between patients and doctors. In the future, AI will show its value in more and more scenarios and help patients and doctors. "
"The combination of artificial intelligence and medical care will likely improve the efficiency of different links in the entire medical industry chain, from genomics research to screening and development of vaccines and drugs to clinical auxiliary diagnosis," said Yuan Jingru, vice president of artificial intelligence at Huawei Cloud.
According to Ma Chunxi, co-founder and CEO of Qian Kun Science and Technology, the real problems such as the scarcity and uneven distribution of medical resources make many people look down on the disease. The beauty of AI technology is that every ordinary person can enjoy medical services fairly, which is also the mission of AI medical enterprises. I hope Qian Kun Science and Technology will make the greatest contribution to smart medical care in the future.
Solving pain points Kun Ai is frequently used by clinicians.
For many start-ups, the application of AI in the field of medical diagnosis and treatment is facing the competition of Internet giants, but there are not many enterprises that can really realize commercialization in the medical field. Qian Kun Science and Technology is undoubtedly the first AI enterprise to realize clinical value.
A few years ago, Ma Chuen saw that the products on the market were seriously homogenized, with the focus on the screening of pulmonary nodules and sugar nets. She firmly believes that only products with great clinical value will be commercialized for a long time. At the end of 2020, Jikun Technology obtained the world's first Class III certificate of AI medical devices for coronary artery stenosis, and it has been rapidly deployed in more than 600 hospitals across the country.
In addition, most domestic AI imaging products are based on two-dimensional medical images to develop auxiliary diagnostic products. On the other hand, under the idea of building a digital human body, Jikun Technology has successively built digital heart, digital brain, digital lung, digital abdomen and other products.
Ma Chune introduced that when building a "digital heart", several Kun technologies first reconstructed the film of the fault and established a complete heart in a three-dimensional way for doctors to make further diagnosis. This is not a detection of plaque in the heart, and doctors need to do a lot of work.
Ma Chune said that starting from the above cognition, Ji Kun's team first digitized organs. For example, when making head and neck products, the whole anatomical structure of the head and neck should be digitized first, then the diagnostic thinking of the imaging doctor should be simulated, and the abnormalities in the structure should be found, and then the report should be written qualitatively and quantitatively, which can conform to the thinking mode of the imaging doctor.
"So when our digital heart was deployed in clinical daily work, doctors liked it very much, and we made digital brains and other products along this line," Ma Chune said. "From a technical point of view, detecting lesions is a relatively simple task, but it can provide some value. What we are thinking about is how to deepen the value of products and make products that clinicians particularly like, especially to solve more complicated scenes such as heart and brain. "
Another reason why clinicians like to count AI is that the intervention of AI reconstructs the workflow of image diagnosis and treatment. From scanning images to structured reports, it can be shortened from two or three hours to two or three minutes now, which greatly saves the time of clinicians and reduces the queuing time of more patients.
AI landing allows more ordinary people to enjoy quality medical care.
Solved the pain points of clinicians, and commercialization naturally came.
Ma Chunxi said that after several Kun's cardiovascular AI diagnostic products passed the certification last year, many hospitals were willing to purchase independently, and some other hospitals hoped that the equipment suppliers would match several Kun's products and the hospitals would purchase them when negotiating the purchase contract with the suppliers of large equipment. More and more equipment manufacturers take the initiative to develop strategic cooperation with several Kun. Several Kun don't need to sell products one by one, and the standards of several Kun AI products of large equipment manufacturers can also enhance their value and give customers better solutions.
Ma Chunxi said that Ji Kun hopes that every image can become an AI auxiliary report, and every operation can be assisted by AI products. Commercialization is only a process from quantitative change to qualitative change, and more ordinary people will enjoy high-quality top three medical resources faster.
In order to achieve this goal, several Kun technology quickly laid out channels to sink, and constantly pushed AI to grassroots county hospitals.
According to the People's Daily Health Client, at the end of last year, xinghua city People's Hospital introduced the digital brain, digital heart and digital lung artificial intelligence imaging system developed and produced by several Kun technologies. After two days of installation training, doctors in hospital imaging department have been able to skillfully use the system to diagnose patients intelligently.
Liu Xingming, director of the CT room of the hospital, said, "The CTA artificial intelligence aided diagnosis system for coronary artery and head and neck introduced by the hospital is very helpful to improve medical efficiency and quality, and now it is frequently used in clinic every day. For some intractable diseases, patients still don't trust our diagnosis. After hearing the artificial intelligence and the report issued by the doctor, the patient eliminated his doubts. "
Leaving patients at home, liberating imaging doctors from tedious watching films, and bringing the experience of doctors in top three hospitals to the grassroots level, AI has effectively improved the diagnostic ability of grassroots hospitals, so that the graded diagnosis and treatment system can truly take root in grassroots hospitals and patients.
Nowadays, Ji Kun 'ai has become an indispensable medical diagnostic tool for many doctors, and has formed a highly viscous relationship with doctors and patients. And this dependence and high viscosity are the most concerned investment decision-making basis for investment institutions. On February 28th last year, 12, Jikun Technology completed a new round of financing of RMB 590 million, which was led by Sequoia Capital China. Last year, Jikun Technology completed nearly 654.38 billion yuan of financing and became a leader in the field of AI imaging.